InterPAD - DETAILS

Empagliflozin, 864070-44-0, JARDIANCE, BI 10773, BI10773, BI-10773, Empagliflozin (BI 10773), UNII-HDC1R2M35U, HDC1R2M35U, (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, CHEBI:82720, 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene, (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol, GLYXAMBI COMPONENT EMPAGLIFLOZIN, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol, TRIJARDY XR COMPONENT EMPAGLIFLOZIN, (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL, D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-, Empagliflozin (BI-10773;BI 10773;BI10773), (1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXAN-3-YL)OXY)PHENYL)METHYL)PHENYL)-D-GLUCITOL, (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol, (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, Empagliflozin [INN], Empagliflozin [USAN:INN], Empagliflozina, Empagliflozine, Empagliflozinum, C23H27ClO7, MFCD22566222, Jardiance (TN), (1S)-1,5-anhydro-1-(4-chloro-3-(4-((3S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-D-glucitol, (1S)-1,5-Anhydro-1-C-(4-chloro-3-((4-(((3S)-oxolan-3-yl)oxy)phenyl)methyl)phenyl)-D-glucitol, 7R3, D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)-; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; BI 10773; Empagliflozin; Jardiance, EMPAGLIFLOZIN [MI], BI-10773;Empagliflozin, EMPAGLIFLOZIN [JAN], EMPAGLIFLOZIN [USAN], Empagliflozin (BI10773), EMPAGLIFLOZIN [VANDF], SCHEMBL899986, EMPAGLIFLOZIN [WHO-DD], GTPL4754, CHEMBL2107830, Empagliflozin (JAN/USAN/INN), A10BK03, AMY1858, EX-A414, BDBM150162, DTXSID601026093, EMPAGLIFLOZIN [ORANGE BOOK], BBL104150, HB4638, s8022, STL557964, US8980829, EMPAGLIFLOZIN, AKOS024464680, CCG-269242, CS-0940, DB09038, DS-9824, PB23119, AC-27643, EMPAGLIFLOZIN COMPONENT OF GLYXAMBI, EMPAGLIFLOZIN COMPONENT OF SYNJARDY, HY-15409, EMPAGLIFLOZIN COMPONENT OF TRIJARDY XR, SW219120-1, C22194, D10459, EN300-7422890, A852380, AU-004/43508285, Q5373824, Z2235802079, 1,5-anhydro-1-{4-chloro-3-[4-(tetrahydro-3-furanyloxy)benzyl]phenyl}hexitol, (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol

Name	Empagliflozin
PubChem CID	11949646
Molecular Weight	450.9g/mol
Synonyms	Empagliflozin, 864070-44-0, JARDIANCE, BI 10773, BI10773, BI-10773, Empagliflozin (BI 10773), UNII-HDC1R2M35U, HDC1R2M35U, (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, CHEBI:82720, 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene, (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol, GLYXAMBI COMPONENT EMPAGLIFLOZIN, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol, TRIJARDY XR COMPONENT EMPAGLIFLOZIN, (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL, D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-, Empagliflozin (BI-10773;BI 10773;BI10773), (1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXAN-3-YL)OXY)PHENYL)METHYL)PHENYL)-D-GLUCITOL, (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol, (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol, Empagliflozin [INN], Empagliflozin [USAN:INN], Empagliflozina, Empagliflozine, Empagliflozinum, C23H27ClO7, MFCD22566222, Jardiance (TN), (1S)-1,5-anhydro-1-(4-chloro-3-(4-((3S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-D-glucitol, (1S)-1,5-Anhydro-1-C-(4-chloro-3-((4-(((3S)-oxolan-3-yl)oxy)phenyl)methyl)phenyl)-D-glucitol, 7R3, D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)-; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; BI 10773; Empagliflozin; Jardiance, EMPAGLIFLOZIN [MI], BI-10773;Empagliflozin, EMPAGLIFLOZIN [JAN], EMPAGLIFLOZIN [USAN], Empagliflozin (BI10773), EMPAGLIFLOZIN [VANDF], SCHEMBL899986, EMPAGLIFLOZIN [WHO-DD], GTPL4754, CHEMBL2107830, Empagliflozin (JAN/USAN/INN), A10BK03, AMY1858, EX-A414, BDBM150162, DTXSID601026093, EMPAGLIFLOZIN [ORANGE BOOK], BBL104150, HB4638, s8022, STL557964, US8980829, EMPAGLIFLOZIN, AKOS024464680, CCG-269242, CS-0940, DB09038, DS-9824, PB23119, AC-27643, EMPAGLIFLOZIN COMPONENT OF GLYXAMBI, EMPAGLIFLOZIN COMPONENT OF SYNJARDY, HY-15409, EMPAGLIFLOZIN COMPONENT OF TRIJARDY XR, SW219120-1, C22194, D10459, EN300-7422890, A852380, AU-004/43508285, Q5373824, Z2235802079, 1,5-anhydro-1-{4-chloro-3-[4-(tetrahydro-3-furanyloxy)benzyl]phenyl}hexitol, (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
Drug Type	Small molecule
Formula	C₂₃H₂₇ClO₇
SMILES	C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
InChI	1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
InChIKey	OBWASQILIWPZMG-QZMOQZSNSA-N
CAS Number	864070-44-0
ChEMBL ID	CHEMBL2107830
ChEBI ID	CHEBI:82720
TTD ID	D06ALD
Drug Bank ID	DB09038
KEGG ID	D10459
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Empagliflozin
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.